Stem cell therapy may help reduce pain and improve function in some people with advanced knee osteoarthritis, but it cannot reliably rebuild a severely worn joint surface. When a knee has reached true bone-on-bone degeneration, the amount of remaining cartilage and overall joint structure become important limitations.

Clinical studies of mesenchymal stem or stromal cells, or MSCs, have reported improvements in pain and function in knee osteoarthritis. However, more recent research also suggests that patients with less severe osteoarthritis may experience greater improvement than those with advanced disease. Structural cartilage restoration has not been consistently demonstrated.

For this reason, a bone-on-bone knee needs to be assessed differently from early or moderate osteoarthritis.

What Does “Bone-on-Bone Knee” Actually Mean?

Bone-on-bone usually describes advanced knee osteoarthritis where the space between the bones has become severely narrowed because much of the protective articular cartilage has been lost.

On an X-ray, a healthy knee normally shows space between the femur and tibia. The cartilage itself is not directly visible on a standard X-ray, but the space between the bones gives doctors an indication of how much cartilage remains.

As osteoarthritis progresses, this joint space becomes narrower. In advanced osteoarthritis, the knee may also develop bone spurs, changes in the bone underneath the cartilage, deformity, and altered alignment. Bone-on-bone changes may affect only one compartment of the knee, such as the medial side, or may involve several parts of the joint. This distinction matters because two patients who are both told they have a “bone-on-bone knee” may still have very different symptoms, alignment, remaining cartilage, and treatment options.

What Grade of Osteoarthritis Is Considered Bone-on-Bone?

Bone-on-bone changes are commonly associated with advanced radiographic osteoarthritis, particularly Kellgren-Lawrence Grade 4.

Grade 4 osteoarthritis typically involves marked joint-space narrowing together with significant osteophytes and changes in the underlying bone. However, treatment decisions should not be made from the X-ray grade alone.

Some patients with significant radiographic arthritis remain relatively active, while others experience substantial pain, stiffness, and loss of mobility. The physician therefore needs to consider both the structure of the knee and how much the condition affects the patient’s daily life.

How Can Stem Cells Help Knee Osteoarthritis?

MSC therapy is primarily studied for its biological effects inside the osteoarthritic joint.

UC-MSCs can release signaling molecules that interact with inflammatory and immune pathways. These paracrine and immunomodulatory effects may help create a more favorable biological environment within the joint.

Clinical studies have reported improvements in pain, symptoms, and physical function after intra-articular MSC treatment for knee osteoarthritis. A 2026 systematic review of randomized controlled trials reported improvements across several pain and functional measures following MSC-based treatment. Another 2026 analysis examining cell therapy together with rehabilitation reported improvements in subjective pain and function and found that patients with less severe osteoarthritis tended to show greater improvements in pain.

This is important when considering a bone-on-bone knee. MSC treatment may influence pain and inflammation, but its ability to help becomes more limited when the main problem is extensive structural loss.

Can Stem Cells Regrow Cartilage in a Bone-on-Bone Knee?

Patients should not expect a stem cell injection to rebuild an entire joint surface that has already been lost. Research continues to investigate whether MSC therapies can influence cartilage repair and joint structure. However, clinical improvements in pain and function do not necessarily mean that large amounts of cartilage have grown back.

A 2026 meta-analysis of randomized trials found improvements in several patient-reported outcomes after MSC treatment, but MRI-based structural measures did not show consistent improvement. This distinction is particularly important in advanced osteoarthritis.

A joint with moderate cartilage loss still has existing tissue and structure that can potentially benefit from an improved biological environment. A severely collapsed joint has less remaining structure to support. Stem cell therapy should therefore not be presented as a way to recreate a completely normal knee from an end-stage bone-on-bone joint.

Does That Mean Stem Cells Cannot Help Advanced Osteoarthritis?

Not necessarily. Some patients with advanced osteoarthritis may still experience improvement in symptoms following regenerative treatment.

Pain in osteoarthritis does not come from cartilage alone. Inflammation within the joint, synovial irritation, bone changes, muscle weakness, and other surrounding tissues can all contribute to symptoms. Because MSC therapy may influence inflammatory signaling, some patients may experience reduced pain even when the structural arthritis remains visible on imaging.

This means a patient can potentially feel better without the X-ray becoming normal. The important question is what the patient expects from treatment. If the goal is to reduce symptoms and maintain function for a period of time, regenerative treatment may be considered in selected cases. If the expectation is to completely restore the joint surface and permanently avoid surgery despite severe structural collapse, that expectation would not be realistic.

Why Do Patients With More Remaining Cartilage Often Have a Better Opportunity to Respond?

Regenerative treatment works within the structure that remains. In earlier and moderate stages of osteoarthritis, the joint may still have substantial cartilage, reasonably preserved alignment, and better mechanical function. This provides a more favorable environment for a biological treatment.

In contrast, advanced osteoarthritis may involve cartilage loss, joint-space collapse, bone remodeling, deformity, meniscal damage, and altered alignment. Stem cells cannot mechanically correct these changes. A 2026 systematic review examining rehabilitation and MSC treatment found that less severe osteoarthritis was associated with greater improvements in subjective pain following cell-based injections.

This supports an important clinical principle: the stage of joint damage matters when deciding whether regenerative treatment is appropriate.

Can Stem Cells Correct Bow Legs or Knock Knees From Osteoarthritis?

No. Stem cell therapy cannot mechanically correct major alignment problems. Advanced knee osteoarthritis can cause the leg to gradually become more bow-legged or knock-kneed as one side of the joint wears more than the other.

When the underlying problem is significant malalignment, the forces passing through the knee remain abnormal even if inflammation improves. This is one reason imaging and orthopedic assessment are important before treatment. Biological treatment may address the joint environment, but it cannot straighten a structurally deformed knee.

Can Stem Cells Increase the Joint Space in a Bone-on-Bone Knee?

Patients should not expect stem cell treatment to reliably restore severely lost joint space.

Joint-space narrowing reflects structural cartilage loss and changes within the knee. While regenerative research continues to investigate cartilage repair, current clinical evidence does not demonstrate predictable restoration of advanced joint-space loss after an MSC injection. This does not mean that symptom improvement is impossible. Pain relief and structural regeneration are different outcomes. A patient may walk more comfortably even though follow-up imaging still shows significant osteoarthritis.

When Might Stem Cell Therapy Still Be Considered for a Bone-on-Bone Knee?

The decision depends on the individual knee rather than the phrase “bone-on-bone” alone. Regenerative treatment may still be discussed when a patient wants to manage symptoms, remains reasonably functional, understands that the structural arthritis will remain, and is not yet ready or suitable for knee replacement.

Age, overall health, pain level, activity, alignment, range of motion, muscle strength, weight, previous treatments, and imaging findings all matter. The physician also needs to understand why the patient wants to postpone surgery. For some patients, the goal may be to continue working, travelling, exercising at a modified level, or maintaining daily function before eventually considering replacement. In these situations, the objective should be clearly defined before treatment.

When Is Knee Replacement More Appropriate?

Knee replacement becomes increasingly relevant when advanced structural damage is accompanied by substantial pain and loss of function despite appropriate nonsurgical treatment. Knee replacement addresses a different problem from regenerative therapy.

It mechanically replaces the severely damaged joint surfaces rather than attempting to modify the biological environment of the existing joint. A 2025 guideline update states that knee arthroplasty may be appropriate for patients with radiographically confirmed moderate to severe osteoarthritis, particularly Kellgren-Lawrence Grade 3 or 4, when symptoms remain significant despite nonsurgical treatment.

Similarly, the American College of Rheumatology and American Association of Hip and Knee Surgeons recommend that patients with symptomatic moderate to severe osteoarthritis who have already failed appropriate nonsurgical treatment should not automatically delay indicated joint replacement simply to continue additional injections or other conservative therapies. This does not mean every Grade 4 knee requires immediate surgery. It means that when pain, mobility, deformity, and quality of life have reached the point where replacement is clearly indicated, regenerative treatment should not be presented as an equivalent structural substitute.

Stem Cell Therapy vs Knee Replacement: Are They Competing Treatments?

Not really. They are better understood as treatments suited to different stages and treatment goals.

Stem cell therapy aims to influence the biological environment of the existing joint. Knee replacement mechanically replaces a severely damaged joint surface.

For patients with meaningful cartilage and joint structure remaining, biological treatment may be considered before replacement becomes necessary. For patients with severe structural collapse, substantial deformity, persistent pain, and significant functional limitation, surgery may provide a more predictable mechanical solution.

One treatment does not need to be described as better than the other. The important question is which approach matches the current condition of the joint.

Why Is Imaging Important Before Treating a Bone-on-Bone Knee?

Imaging helps determine whether regenerative treatment has a reasonable treatment target. Weight-bearing X-rays can show joint-space narrowing, alignment, osteophytes, and the overall severity of osteoarthritis.

MRI can provide additional information about remaining cartilage, menisci, bone, ligaments, inflammation, and other structures when needed. For a patient who has already been told they have severe osteoarthritis, reviewing the actual images can be more useful than relying only on the phrase “bone-on-bone.” The physician can then determine whether the pain is primarily related to osteoarthritis or whether another problem is also contributing.

What Should Patients Realistically Expect?

For advanced knee osteoarthritis, the realistic goal of MSC therapy is symptom management and functional support rather than complete structural restoration.

Clinical studies have reported improvements in pain and function after MSC treatment for knee osteoarthritis, but results vary between patients. Structural regeneration is less consistently demonstrated, and patients with less severe disease may have a greater opportunity to respond. The best treatment decision therefore depends on more than the OA grade. A patient with advanced imaging changes but manageable symptoms may make a different decision from someone with severe daily pain, major deformity, reduced mobility, and substantial loss of quality of life. The purpose of medical evaluation is to determine where the individual patient sits on that spectrum.

Frequently Asked Questions

• Can stem cells help Grade 4 knee osteoarthritis?

Stem cell therapy may help reduce pain and improve function in selected patients with advanced osteoarthritis, but results tend to be less predictable when structural damage is severe. It should not be expected to recreate a normal joint surface.

• Can stem cells regrow cartilage in a bone-on-bone knee?

Current clinical evidence does not show reliable restoration of an entire severely damaged joint surface. MSC treatment may improve symptoms without producing major structural changes on imaging.

• Can I avoid knee replacement with stem cell therapy?

Some patients may be able to manage symptoms and postpone surgery, particularly when function remains reasonable. In advanced osteoarthritis with severe pain, deformity, or major functional loss, stem cell therapy should not be considered a guaranteed replacement for arthroplasty.

• What stage of knee osteoarthritis responds best to stem cells?

Clinical research suggests patients with less severe osteoarthritis may experience greater improvement than those with advanced disease. The amount of remaining cartilage, joint alignment, symptoms, and overall knee structure all influence treatment selection.

• Does bone-on-bone always mean I need knee replacement immediately?

No. Imaging alone does not determine the timing of surgery. Pain, function, quality of life, deformity, response to nonsurgical treatment, medical fitness, and patient goals all need to be considered.

Medically reviewed by Dr. Naputt Virasathienpornkul, M.D. Orthopedic Surgeon, Sports Medicine & Joint Conditions

Related Reading

• Stem Cell Therapy for Knee Osteoarthritis in Bangkok
• Can You Exercise After a Stem Cell Injection?
• Why Rehabilitation Matters After Stem Cell Therapy
• Stem Cell Therapy: Benefits, Limitations, and Realistic Expectations

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation:

LINE: @ednawellness
WhatsApp: +66 (0) 64 505 5599
Website: www.ednawellness.com

References

• Cottmeyer DF, Chiu M, Maltusch K, Tsai LC. Towards optimized rehabilitation with regenerative therapy: A systematic review and meta-analysis on the effects of cell-based injections for knee osteoarthritis. Knee Surgery, Sports Traumatology, Arthroscopy. 2026 https://pubmed.ncbi.nlm.nih.gov/41733018/
• Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. 2026. https://pubmed.ncbi.nlm.nih.gov/41863718/
• Tabet CG, et al. Advanced therapy with mesenchymal stromal cells for knee osteoarthritis: Systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Translation. 2024. https://pubmed.ncbi.nlm.nih.gov/39360004/
• Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. 2025. https://pubmed.ncbi.nlm.nih.gov/40055739/
• Lützner J, Deckert S, Lange T, et al. Evidence-based and Patient-centered Indication for Knee Arthroplasty – Update of the Guideline. Zeitschrift für Orthopädie und Unfallchirurgie. 2025. https://pubmed.ncbi.nlm.nih.gov/38810966/
• Hannon CP, Goodman SM, Austin MS, et al. 2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty. Journal of Arthroplasty. 2023. https://pubmed.ncbi.nlm.nih.gov/37778918/